The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

Slides:

Advertisements

Similar presentations

Neurotrophins & NTs Receptors Loredana Lombardi Ariadna Laguna Molecular Mechanisms of Development (EMBO), Barcelona 2006.

Advertisements

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

Samsung Genome Institute Samsung Medical Center

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Structure of the fly LGR2 gene and the corresponding cDNA sequence. A, Derivation of the fly LGR2 full-length cDNA from the genomic sequence.

Structure of the Gene for Congenital Nephrotic Syndrome of the Finnish Type (NPHS1) and Characterization of Mutations Ulla Lenkkeri, Minna Männikkö,

TRKA oncogenic variants and TRK gene fusion partners.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Anna F. Farago, MD, PhD, Long P

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Schematic representation of main EGFR-TKIs resistance mechanisms.

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Congenital Insensitivity to Pain with Anhidrosis: Novel Mutations in the TRKA (NTRK1) Gene Encoding A High-Affinity Receptor for Nerve Growth Factor

Progesterone receptor nuclear morphology patterns in breast cancer.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Anna F. Farago, MD, PhD, Long P

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Flow chart of the used methodology adapted from Moher et al

Detection rate for EGFR mutations in cfDNA.

Mechanism of CTLA-4-induced immunosuppression.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Clustering of Activating Mutations in c-KIT’s Juxtamembrane Coding Region in Canine Mast Cell Neoplasms Yongsheng Ma, B. Jack Longley, Xiaomei Wang

The intrinsic apoptotic pathway is a balance between proapoptotic proteins, for example, Bax and Bak and antiapoptotic proteins. The intrinsic apoptotic.

Kaplan-Meier curves for overall survival (OS) probability.

Methods distribution among the three EQAs

Protein information in the Human Protein Atlas.

Clinical courses of patients.

Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention.

Detection rate of EGFR mutations in cfDNA by characteristics

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Molecular spectra of BTC

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Oncogenic ALK signaling.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Platelet-derived growth factor (PDGF) signalling pathway.

Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

General structure of RIFINs and STEVORs

Proportion of continuous, intermittent, and limited (

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Figure 2 Mechanisms of RET activation in cancer

(A) Survival curves according to clinical response.

Progesterone receptor (PR)A and PRB isoform receptor domains and post-translational modifications. Progesterone receptor (PR)A and PRB isoform receptor.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type.

Prescribers’ responses rating their level of comfort on a scale of 1–5

Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. Oligomerisation of the chimeric protein is the main proposed mechanisms for increased tumour cell survival and proliferation via the known pathways of Trk receptors. (A) NTRK1 gene with 17 exon sequences and respective TrkA protein regions.5 (B) Mechanism of entrectinib (E) action and the known mechanisms of acquired resistance (point mutation G595R and G567C) to E.50 Cys, cysteine clusters; Ig1 and Ig2, first and second immunoglobulin-like motifs, respectively; LRM, leucine-rich motifs; SP, signal peptide; TK, tyrosine kinase; TM, transmembrane. Alessio Amatu et al. ESMO Open 2016;1:e000023 Copyright © European Society for Medical Oncology. All rights reserved.